Collegium Pharmaceutical’s (COLL) “Buy” Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC reiterated their buy rating on shares of Collegium Pharmaceutical Inc. (NASDAQ:COLL) in a research note issued to investors on Wednesday. They currently have a $30.00 price objective on the specialty pharmaceutical company’s stock.
Other equities analysts have also issued research reports about the company. Gabelli initiated coverage on Collegium Pharmaceutical in a research report on Tuesday, September 13th. They issued a buy rating and a $25.00 target price for the company. Piper Jaffray Cos. reissued a buy rating and issued a $27.00 target price (up previously from $26.00) on shares of Collegium Pharmaceutical in a research report on Thursday, June 23rd. Finally, Zacks Investment Research raised shares of Collegium Pharmaceutical from a sell rating to a hold rating in a research report on Tuesday, July 26th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $27.60.
Shares of Collegium Pharmaceutical (NASDAQ:COLL) opened at 10.53 on Wednesday. Collegium Pharmaceutical has a 12 month low of $8.24 and a 12 month high of $30.58. The firm’s 50-day moving average is $10.57 and its 200 day moving average is $14.52. The company’s market capitalization is $247.75 million.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.29. Equities analysts expect that Collegium Pharmaceutical will post ($3.86) EPS for the current year.
In other Collegium Pharmaceutical news, Director John A. Fallon purchased 2,375 shares of Collegium Pharmaceutical stock in a transaction dated Friday, August 12th. The stock was purchased at an average price of $10.59 per share, with a total value of $25,151.25. Following the transaction, the director now directly owns 2,375 shares of the company’s stock, valued at $25,151.25. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 37.93% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Nationwide Fund Advisors raised its stake in Collegium Pharmaceutical by 73.3% in the second quarter. Nationwide Fund Advisors now owns 8,665 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 3,665 shares in the last quarter. Alliancebernstein L.P. purchased a new stake in Collegium Pharmaceutical during the second quarter valued at about $122,000. Royal Bank of Canada raised its stake in Collegium Pharmaceutical by 2.7% in the second quarter. Royal Bank of Canada now owns 11,600 shares of the specialty pharmaceutical company’s stock valued at $137,000 after buying an additional 300 shares in the last quarter. Rhumbline Advisers purchased a new stake in Collegium Pharmaceutical during the second quarter valued at about $143,000. Finally, A.R.T. Advisors LLC purchased a new stake in Collegium Pharmaceutical during the second quarter valued at about $148,000. 62.13% of the stock is owned by institutional investors.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.